Company news

Altimmune, Inc. news in 2022

Altimmune, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

December 19, 2022

Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

November 9, 2022

Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

September 27, 2022

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

September 13, 2022

Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update

August 10, 2022

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

June 16, 2022

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

May 30, 2022

Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update

May 11, 2022

Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

May 4, 2022

Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity

March 31, 2022

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

March 14, 2022

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

March 7, 2022

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

January 30, 2022

Calls in 2022

Decks in 2022